259180-78-4 Usage
Uses
Used in Pharmaceutical Industry:
Tert-butyl 2-(2-aminoethyl)morpholine-4-carboxylate is used as a building block in the synthesis of various pharmaceutical compounds for [application reason]. Its unique structure and properties make it a potentially valuable component in the development of new drugs with improved efficacy and safety profiles.
Used in Medicinal Chemistry Research:
Tert-butyl 2-(2-aminoethyl)morpholine-4-carboxylate is used as a research tool in medicinal chemistry to explore its potential as a lead compound for the development of new therapeutic agents. Its unique structural features and chemical properties make it an interesting candidate for further investigation and optimization in the search for novel drug candidates.
Check Digit Verification of cas no
The CAS Registry Mumber 259180-78-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,9,1,8 and 0 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 259180-78:
(8*2)+(7*5)+(6*9)+(5*1)+(4*8)+(3*0)+(2*7)+(1*8)=164
164 % 10 = 4
So 259180-78-4 is a valid CAS Registry Number.
259180-78-4Relevant articles and documents
PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES
-
Page/Page column 33; 57; 58, (2019/11/04)
The present invention relates to pyrazolo [1,5 -a] [1,3,5 ]triazine and pyrazolo[1,5-a] pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazo lo [1,5-a][1,3,5 ]triazine and pyrazolo [1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.
MORPHOLINYLMETHYLUREAS CCR-3 RECEPTOR ANTAGONISTS
-
Page/Page column 33, (2010/02/07)
Compounds of formula (I'): (I); wherein: R1 represents substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; X represents -(CRkaRkb)k-; Rka and Rkb are each independ